Humabiologics has launched a research-grade human collagen product designed to support scientific research amid increasing funding constraints. The new biomaterial, part of the company's HumaDerm product line, offers researchers an affordable and ethically sourced alternative to traditional research materials.
The product addresses critical challenges facing life sciences researchers, particularly in regenerative medicine, drug testing, and tissue modeling. With recent federal budget cuts impacting NIH and NSF grants, the new collagen provides a cost-effective solution for maintaining scientific progress.
Mohammad Albanna, PhD, Founder and CEO of Humabiologics, emphasized the importance of supporting researchers during challenging funding environments. The human collagen is sourced from FDA-registered and AATB-accredited tissue banks, utilizing tissues not suitable for transplantation but valuable for scientific research.
Tim Bertram from the National Science Foundation Piedmont Triad Regenerative Medicine Engine highlighted the significance of this innovation, noting that it eliminates cost barriers that have historically compromised research quality. By offering human-derived biomaterials at a price point below animal alternatives, Humabiologics is potentially accelerating the translation of research into clinical solutions.
The launch builds on the company's recent grant from the Piedmont Triad Regenerative Medicine Engine and represents a strategic collaboration with institutions like the Wake Forest Institute for Regenerative Medicine. This development could significantly impact tissue engineering, wound healing, and drug discovery research by providing more physiologically relevant research materials.
